IH, Brain Health, and T2D
Part of paid clinical trials in Iowa City, Iowa.
- Sponsor
- Darren P Casey
- Study ID
- NCT07173543
- Status
- Recruiting
Conditions
- Aging
- Type 2 Diabetes
Eligibility Criteria
- Sex
- ALL
- Age
- 60 Years - 85 Years
- Healthy Volunteers
- Accepted
Interventions
- Intermittent Hypoxia 1 (IH1) — OTHERIntermittent Hypoxia 1 (IH1): 5 cycles of normoxia (4 minutes)/hypoxia (6 minutes) per session. 3 sessions per week for 8 weeks
- Intermittent Hypoxia 2 (IH2) — OTHERIntermittent Hypoxia 1 (IH2): 5 cycles of normoxia (4 minutes)/hypoxia (6 minutes) per session. 3 sessions per week for 4 weeks
- SHAM - normoxia — OTHERParticipants will receive normoxia (no hypoxia) over 50 minutes.
Study Details
The purpose of this study is to use a randomized, placebo-controlled study design to rigorously examine the therapeutic potential of intermittent hypoxia (IH) for improving cerebrovascular health in older adults with and without type 2 diabetes mellitus (T2DM).
Key Dates
- Start date
- Sep 22, 2025
- Status verified
- Mar 2026
- Primary completion
- Jun 30, 2028
- Completion
- Jun 30, 2028
Study Design
- Enrollment
- 80 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Experimental: Intermittent Hypoxia 1Participants will receive intermittent hypoxia (5 cycles of normoxia/hypoxia over 50 minutes).
- Sham Comparator: NormoxiaParticipants will receive normoxia over 50 minutes.
- Experimental: Intermittent Hypoxia 2Participants will receive intermittent hypoxia (5 cycles of normoxia/hypoxia over 50 minutes).
Primary Outcome Measure
Internal Carotid Artery (ICA) shear-mediated dilation [ Time Frame: Baseline and post 2-,4-,5-,6-, and 8-weeks ]
Central Contacts
- Darren Casey, PHD13193841009
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Iowa | Iowa City | Iowa | 52242 | Darren P Casey, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Iowa City, IA
By condition
By specialty
By research site
Related Studies
- Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II DiabetesRecruiting · Endogenex, Inc. · Birmingham, Alabama
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)PHASE3 · Recruiting · Eli Lilly and Company · Tucson, Arizona
- Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)PHASE2 · Recruiting · Sparrow Pharmaceuticals · Chandler, Arizona
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightPHASE3 · Recruiting · Novo Nordisk A/S · Birmingham, Alabama